Microbix BiosystemsMBXBF 51 3-Year ROIIC % is -73.56 as of Sep. 2025. GuruFocus rates MBXBF with a GF Score™ of 51/100 and a GF Value™ of $0.18 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,319 Biotechnology companies, Microbix Biosystems ranks worse than 69.67% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Microbix Biosystems's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was -73.56%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Microbix Biosystems's 3-Year ROIIC % or its related term are showing as below:
MBXBF's 3-Year ROIIC % is ranked worse than 69.67% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs MBXBF: -73.56
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Microbix Biosystems 3-Year ROIIC % Related Terms
Microbix Biosystems 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBXBF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Microbix Biosystems's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's 3-Year ROIIC % falls into.
Microbix Biosystems's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.111664 (Sep. 2025) - 1.8757845 (Sep. 2022) )
/
( 16.857 (Sep. 2025) - 13.365 (Sep. 2022) )
=
-2.9874485
/
3.492
=
-85.55%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Microbix Biosystems (MBXBF) has a 3-Year ROIIC % of -73.56 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #919 out of 1319 companies in the Biotechnology industry, placing it in the top 69.7%.
Is Microbix Biosystems' 3-Year ROIIC % too high?
Microbix Biosystems' current 3-Year ROIIC % is -73.56. Based on the distribution chart, Microbix Biosystems ranks #919 out of 1319 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #919 out of 1319 companies for 3-Year ROIIC %. This places Microbix Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current 3-Year ROIIC % is -73.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (MBXBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.18, compared to a current price of $0.22 — trading 19.4% above its estimated fair value. The current 3-Year ROIIC % is -73.56. Microbix Biosystems' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Microbix Biosystems (MBXBF), the current 3-Year ROIIC % is -73.56 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (MBXBF) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of $0.22 is trading 19.4% above its estimated GF Value™ of $0.18.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for MBXBF:
3-Year ROIIC %: -73.56
GF Value™: $0.18 vs. price of $0.22 (19.4% above fair value)
No single metric tells the full story. See the MBXBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
51GF Score
Get the complete analysis for MBXBF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBXBF has been successfully added to your 
